Investment & M&A transaction comps
Vitamins Investment & M&A Transaction Comps
Explore investment and M&A transactions tagged vitamins. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.
Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.
- Reviewed transactions
- 14
- With value data
- 10
- With revenue multiples
- 10
- Transaction years
- 2012–2026
Sortable transaction comps
Vitamins transaction table
Rows with reported value
10 / 14
Acquisition EV, USD
USD 18B
Investment EV, USD
-
Median EV / revenue
3.6x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
14 shown of 14 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thorne Control | 2026-08-04 | Procter & Gamble | USD 3.8B Consideration | 3,800 | 7.6x | - | United States | Estimated 3 sources | ||
| Vitabiotics Control | 2026-07-24 | Bain Capital | USD 1.0B Estimated Enterprise Value | 1,038 | - | - | United Kingdom | Confirmed 3 sources | ||
| Sunday Natural Control (55%) | 2024-01-15 | CVC Capital Partners | EUR 800M Enterprise Value | 875 | 8.0x | 16.0x | Germany | Estimated 1 source | ||
| Blackmores Control (100%) | 2023-04-26 | Kirin | USD 1.2B Enterprise Value | 1,241 | 2.9x | 23.1x | Australia | Estimated 3 sources | ||
| 2021-04-30 | Nestlé | USD 5.8B Consideration | 5,750 | 3.1x | 16.8x | - | Confirmed 1 source | |||
| Smarty Pants Control | 2020-11-25 | Unilever | Undisclosed | Undisclosed | 4.0x | - | - | Confirmed 1 source | ||
| Care/of Control | 2020-08-31 | Bayer | USD 225M | 225 | - | - | United States | Confirmed 1 source | ||
| Nutranext Control | 2018-03-12 | Clorox | USD 700M Consideration | 700 | 3.5x | 14.0x | - | Estimated 1 source | ||
| Atrium Innovations Control | 2017-12-05 | Nestlé | USD 2.3B Consideration | 2,300 | 3.3x | 19.0x | - | Confirmed 1 source | ||
| Vitaco Control | 2016-08-01 | Primavera Capital | Undisclosed | Undisclosed | 1.5x | 14.7x | Australia/New Zealand | Confirmed 1 source | ||
| Swisse Control (83%) | 2015-09-17 | Biostime | AUD 1.7B Enterprise Value | 1,197 | 3.6x | 10.2x | Australia | Confirmed 2 sources | ||
| Schiff Nutrition Control | 2012-11-22 | Reckitt Benckiser | Undisclosed | Undisclosed | 4.2x | 19.1x | - | Confirmed 1 source | ||
| Twinlab Control | - | cbdMD | Undisclosed Consideration | Undisclosed | - | - | - | Confirmed 2 sources | ||
| Nestlé Holistic Health Platform Control | - | Yellow Wood Partners | USD 1.0B Consideration | 1,000 | - | - | - | Confirmed 2 sources |
Explore related tags
Continue to the full transaction history for each tag.
Explore buyers & investors
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.